Jing Christine Ye, M.D., MSc
Department of Lymphoma - Myeloma, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1996 | Jiao Tong University, Shanghai, CHN, MS, Bioscience |
| 1993 | Jiao Tong University, Shanghai, CHN, MD, Medicine |
Postgraduate Training
| 2012-2015 | Clinical Fellowship, Hematology Oncology, Wayne State University, Karmanos Cancer Institute, Detroit, MI |
| 2009-2012 | Clinical Residency, Internal Medicine, Wayne State University, Detroit Medical Center, Detroit, MI |
| 1996-1997 | Research Fellowship, The Hospital for Sick Children, Toronto |
Board Certifications
| 2016 | American Board of Internal Medicine- Hematology |
| 2015 | American Board of Internal Medicine- Oncology |
| 2012 | American Board of Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor, Department of General Internal Medicine, Division of Hematology Oncology, University of Michigan, Michigan Medicine, Ann Arbor, MI, 2021 - 2023
Assistant Professor, Department of General Internal Medicine, Division of Hematology Oncology, University of Michigan, Ann Arbor, MI, 2015 - 2021
Institutional Committee Activities
Member, University of Michigan Rogel Cancer Center Protocol Review Committee, 2021 - 2023
Honors & Awards
| 2017 | Clinical Trial Academy |
Selected Publications
Peer-Reviewed Articles
- Janakiram M, Ye JC. Role of Anti–CD38 Antibody Therapy in Induction and Maintenance in Newly Diagnosed Multiple Myeloma: How to Adopt in Clinical Practice. ASCO Daily News, 2023.
- Sankar K, Ye JC, Li Z, Zheng L, Song W, Hu-Lieskovan S. The role of biomarkers in personalized immunotherapy. Biomark Res 10(1):32, 2022.
- Vo JN, Wu YM, Mishler J, Hall S, Vats P, Mannan R, Wang L, Ning Y, Zhou J, Hopkins AC, Estill J, Chan WKB, Yesil J, Cao X, Rao A, Tsodikov A, Talpaz M, Cole CE, Ye JC, Bergsagel L, Auclair D, Robinson DR, Chinnaivan AM. The Genetic Heterogeneity and Drug Resistance Mechanisms of Relapsed Refractory Multiple Myeloma. Nat Commun 13(1):3750, 2022.
- Hou JZ, Ye JC, Pu JJ, Liu H, Ding W, Zheng H, Liu D. Novel agents and regimens for hematological malignancies 14(1):66, 2021.
- Ye JC, Horne S, Zhang JZ, Jackson L, Heng HH. Therapy Induced Genome Chaos: A Novel Mechanism of Rapid Cancer Drug Resistance. Front Cell Dev Biol, 2021.
- Su CT, Ye JC. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond 14(1):115, 2021.
- Hoylman E, Brown A, Perissinotti AJ, Marini BL, Pianko M, Ye JC, Campagnaro E, Nachar VR. Optimal Sequence Of Daratumumab And Elotuzumab In Relapsed And Refractory Multiple Myeloma. Leuk Lymphoma 61(3):691-698, 2020.
- Ye JC, Chen J, Liu G, Heng HH. Somatic Genomic Mosaicism in Multiple Myeloma. Front Genet 11:388, 2020.
- Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell R, Holstein S, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jkubowiak A, Morgan GJ, Krishnan a, Jacson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, San Miguel J, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B. International Harmonization in Performing and Reporting Minimal Residual Disease Assessment in Multiple Myeloma Trials. Leukemia, 2020.
- Ye JC, Sharpe Z, Heng HH. Origins and Consequences of Chromosomal Instability: From Cellular Adaptation to Genome Chaos-Mediated System Survival. Genes 11(10):1162, 2020.
- Modi D, Ye JC, Surapaneni M, Singh V, Chen W, Jang H, Deol A, Ayash L, Alavi A, Ratanatharathorn V, Uberti JP. Liver Graft-Versus-Host Disease is associated with poor survival among allogeneic hematopoietic stem cell transplant recipients. Am J Hematol 94(10):1072-1080, 2019.
- Ye JC, Stilgenbauer L, Moy A, Liu G, Heng HH. What Is Karyotype Coding and Why Is Genomic Topology Important for Cancer and Evolution?. Front Genet 10:1082, 2019.
- Skala SL, Ye JC, Stumph J, Macon WR, Quinones FR, Khachaturov V, Ketterling RP, Dewar R. Combined Tumors in Hematolymphoid Neoplasms: Case Series of Histiocytic and Langerhans Cell Sarcomas Arising From Low-Grade B-Cell Lymphoma. Clin Pathol, 2019.
- Ye JC, Sharpe Z, Alemara S, Mackenzie S, Liu G, Abdallah B, Horne S, Regan S, Heng HH. Micronuclei and Genome Chaos: Changing the System Inheritance. Genes 10(5):366, 2019.
- Ye JC, Chen L, Chen J, Parkin B, Polk A, Kandarpa M, Cole CE, Campagnaro EL, Robinson D, Wu YM, Talpaz M, Yesil J, Auclair D, Bergsagel PL, Chinnaiyan A, Baladandayuthapani V. Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients. Blood 134:4360, 2019.
- Heng HH, Horne SD, Chaudhry S, Regan SM, Liu G, Abdallah BY, Ye CJ. A Postgenomic Perspective on Molecular Cytogenetics. Curr Genomics 19(3):227-239, 2018.
- Holstein SA, Ye JC, Howard A, Bhutani M, Gormley N, Hahn T, Hillengass J, Krishnan A, Landgren CO, Munshi NC, Oliva S, Owen RG, Pasquini MC, Puig N, Weinhold N, Weisel K, McCarthy PL. Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant 77:65, 2018.
- Ye JC, Regan S, Liu G, Alemara S, Heng HH. Understanding aneuploidy in cancer through the lens of system inheritance, fuzzy inheritance and emergence of new genome systems. Mol Cytogenet 11:31, 2018.
- Heng HH, Regan SM, Liu G, Ye CJ. Why It Is Crucial to Analyze Non Clonal Chromosome Aberrations Or NCCAs?. Mol Cytogenet 9:15, 2016.
- Abdallah BY, Horne SD, Kurkinen M, Stevens JB, Liu G, Ye CJ, Barbat J, Bremer SW, Heng HH. Ovarian cancer evolution through stochastic genome alterations: defining the genomic role in ovarian cancer. Syst Biol Reprod Med 60(1):2-13, 2014.
- Liu G, Stevens JB, Horne SD, Abdallah BY, Ye KJ, Bremer SW, Ye CJ, Chen DJ, Heng HH. Genome chaos: Survival strategy during crisis. Cell Cycle 13(4):528-537, 2014.
- Stevens JB, Liu G, Abdallah BY, Horne SD, Ye KJ, Bremer SW, Ye CJ, Krawetz SA, Heng HH. Unstable genomes elevate transcriptome dynamics. Int. J. Cancer 134(9):2074-2087, 2014.
- Heng HH, Liu G, Stevens JB, Abdallah BY, Horne SD, Ye KJ, Bremer SW, Chowdhury SK, Ye CJ. Karyotype heterogeneity and unclassified chromosomal abnormalities. Cytogenet Genome Res 139(3):144-57, 2013.
- Horne SD, Stevens JB, Abdallah BY, Liu G, Bremer SW, Ye CJ, Heng HH. Why imatinib remains an exception of cancer research. J. Cell. Physiol 228(4):665-670, 2013.
- Stevens JB, Abdallah BY, Liu G, Horne SD, Bremer SW, Ye KJ, Huang JY, Kurkinen M, Ye CJ, Heng HH. Heterogeneity of cell death. Cytogenet. Genome Res 139(3):164-173, 2013.
- Heng HH, Bremer SW, Stevens JB, Horne SD, Liu G, Abdallah BY, Ye KJ, Ye CJ. Chromosomal instability (CIN): What it is and why it is crucial to cancer evolution. Cancer Metastasis Rev 32(3-4):325-340, 2013.
- Stevens JB, Horne SD, Abdallah BY, Ye CJ, Heng HH. Chromosomal instability and transcriptome dynamics in cancer. Cancer Metastasis Rev 32(3-4):391-402, 2013.
- Chandrakasan S, Ye CJ, Chitlur M, Mohamed AN, Rabah R, Konski A, Heng HH, Savaşan S. Malignant fibrous histiocytoma two years after autologous stem cell transplant for Hodgkin lymphoma: evidence for genomic instability. Pediatr Blood Cancer 56(7):1143-5, 2011.
- Stevens JB, Abdallah BY, Liu G, Ye CJ, Horne SD, Wang G, Savasan S, Shekhar M, Krawetz SA, Hüttemann M, Tainsky MA, Wu GS, Xie Y, Zhang K, Heng HH. Diverse system stresses: Common mechanisms of chromosome fragmentation. Cell Death Dis 2(6):89, 2011.
- Heng HH, Stevens JB, Bremer SW, Liu G, Abdallah BY, Ye CJ. Evolutionary Mechanisms and Diversity in Cancer Adv. Cancer Res 112:217-253, 2011.
- Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, Abdallah BY, Horne SD, Ye CJ. Decoding the genome beyond sequencing: The new phase of genomic research. Genomics 98(4):242-252, 2011.
- Stevens JB, Abdallah BY, Regan SM, Liu G, Bremer SW, Ye CJ, Heng HH. Comparison of mitotic cell death by chromosome fragmentation to premature chromosome condensation. Mol Cytogenet 3(1):58, 2010.
- Heng HH, Stevens JB, Bremer SW, Ye KJ, Liu G, Ye CJ. The evolutionary mechanism of cancer. J. Cell. Biochem 109(6):1072-1084, 2010.
- Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, Ye CJ. Genetic and epigenetic heterogeneity in cancer: The ultimate challenge for drug therapy. Curr Drug Targets 11(10):1304-1316, 2010.
- Ye CJ, Stevens JB, Liu G, Bremer SW, Jaiswal AS, Ye KJ, Lin MF, Lawrenson L, Lancaster WD, Kurkinen M, Liao JD, Gairola CG, Shekhar MP, Narayan S, Miller FR, Heng HH. Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J Cell Physiol 219(2):288-300, 2009.
- Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu G, Ye CJ. Genetic and epigenetic heterogeneity in cancer: A genome-centric perspective. J. Cell. Physiol 220(3):538-547, 2009.
- Heng HH, Stevens JB, Lawrenson L, Liu G, Ye KJ, Bremer SW, Ye CJ. Patterns of genome dynamics and cancer evolution. Cell. Oncol 30(6):513-514, 2008.
- Ye CJ, Liu G, Bremer SW, Heng HH. The dynamics of cancer chromosomes and genomes. Cytogenet Genome Res 118(2-4):237-46, 2007.
- Stevens JB, Liu G, Bremer SW, Ye KJ, Xu W, Xu J, Sun Y, Wu GS, Savasan S, Krawetz SA, Ye CJ, Heng HH. Mitotic cell death by chromosome fragmentation. Cancer Res 67(16):7686-7694, 2007.
- Ye CJ, Stevens JB, Liu G, Ye KJ, Yang F, Bremer SW, Heng HH. Combined multicolor-FISH and immunostaining. Cytogenet Genome Res 114(3-4):227-34, 2006.
- Heng HH, Stevens JB, Liu G, Bremer SW, Ye KJ, Reddy PV, Wu GS, Wang YA, Tainsky MA, Ye CJ. Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol 208(2):461-72, 2006.
- Heng HH, Liu G, Bremer S, Ye KJ, Stevens J, Ye CJ. Clonal and non-clonal chromosome aberrations and genome variation and aberration. Genome 49(3):195-204, 2006.
- Heng HH, Bremer SW, Stevens J, Ye KJ, Miller F, Liu G, Ye CJ. Cancer progression by non-clonal chromosome aberrations. J. Cell. Biochem 98(6):1424-1435, 2006.
- Heng HH, Goetze S, Ye CJ, Liu G, Stevens JB, Bremer SW, Wykes SM, Bode J, Krawetz SA. Chromatin loops are selectively anchored using scaffold/matrix-attachment regions. J. Cell. Sci 117(7):999-1008, 2004.
- Takeuchi T, Heng HH, Ye CJ, Liang SB, Iwata J, Sonobe H, Ohtsuki Y. Down-regulation of a novel actin- binding molecule, skeletrophin, in malignant melanoma. Am J Pathol 163(4):1395-404, 2003. PMID: 14507647.
- Heng HH, Ye CJ, Yang F, Ebrahim S, Liu G, Bremer SW, Thomas CM, Ye J, Chen TJ, Tuck-Muller C, Yu JW, Krawetz SA, Johnson A. Analysis of marker or complex chromosomal rearrangements present in pre- and post-natal karyotypes utilizing a combination of G-banding, spectral karyotyping and fluorescence in situ hybridization. Clin Genet 63(5):358-67, 2003.
- Schmid C, Heng HH, Rubin C, Ye CJ, Krawetz SA. Sperm nuclear matrix association of the PRM1-- >PRM2-->TNP2 domain is independent of Alu methylation. Mol Hum Reprod 7(10):903-11, 2001.
- Ye CJ, Lu W, Liu G, Bremer SW, Wang YA, Moens P, Hughes M, Krawetz SA, Heng HH. The combination of SKY and specific loci detection with FISH or immunostaining. Cytogenet Cell Genet 93(3-4):195-202, 2001.
- Heng HH, Liu G, Lu W, Bremer S, Ye CJ, Hughes M, Moens P. Spectral karyotyping (SKY) of mouse meiotic chromosomes. Genome 44(2):293-8, 2001.
- Heng HH, Krawetz SA, Lu W, Bremer S, Liu G, Ye CJ. Re-defining the chromatin loop domain Cytogenet. Cell Genet 93(3-4):155-161, 2001.
- Tarsounas M, Heng HH, Ye JC, Pearlman RE, Moens PB. Identification of the mouse beta'-COP Golgi component as a spermatocyte autoantigen in scleroderma and mapping of its gene Copb2 to mouse chromosome 9. Cytogenet Cell Genet 87(3-4):201-4, 1999.
- Omori F, Messner HA, Ye JC, Gronda MV, O'Neill JP, Atkins H, Heng HH. Nontargeted stable integration of recombinant adeno-associated virus into human leukemia and lymphoma cell lines as evaluated by fluorescence in situ hybridization. Hum Gene Ther 10(4):537-43, 1999.
- Ye J, Cao Q, Su X, Huang Q, Ma Z, Wang Z, Huang W, Chen Z, Chen S. Biological and clinical significance of cytogenic study on 100 acute lymphoblastic leukemia and 219 acute non-lymphoblastic leukemia. Chin Med J (Engl) 110(2):90-5, 1997.
- Chen SJ, Cao Q, Ma ZG, Su XY, Xong SM, Ye J, Wang ZY, Li XS, Shen ZX, Zhang FQ, Sun GL, Fang ZW, Ouyang RR, Zhu XH, Ying DM, Gu LJ, Chen Z. Cytogenic analysis and its prognostic significance in acute non-lymphoblastic leukemia. Chinese Journal of Hematology, 1996.
- Mao M, Yu M, Tong JH, Ye J, Zhu J, Huang QH, Fu G, Yu L, Zhao SY, Waxman S, Lanotte M, Wang ZY, Tan JZ, Chan SJ, Chen Z. RIG-E, a human homolog of the murine Ly-6 family, is induced by retinoic acid during the differentiation of acute promyelocyctic leukemia cell. Proc Natl Acad Sci U S A:5910-4, 1996. PMID: 8650192.
Book Chapters
- Chen J, Ye JC. Chronic Lymphocytic Leukemia. In: Oncology Board Review, 2022.
- Ye, J.C., Regan, S., Liu, G., Abdallah, B., Horne, S., Heng, H.H. Unclassified Chromosome Abnormalities and Genome Behavior in Interphase. In: Human Interphase Chromosomes, 2020.
- Heng, H.H., Liu, G., Alemara, S., Regan, S., Armstrong, Z., Ye, J.C. The Mechanisms of How Genomic Heterogeneity Impacts Bio-Emergent Properties: The Challenges for Precision Medicine. In: Embracing Complexity in Health, 2019.
- Heng HH, Liu G, Ye JC. Experimental Induction of Genome Chaos. In: Methods Mol Biol, 337-352, 2018.
- Ye JC, Heng HH. High Resolution Fiber-Fluorescence In Situ Hybridization. In: Methods Mol Biol Protocols and Applications, 151-166, 2017.
- Ye JC, Liu G, Heng HH. Simultaneous Fluorescence Immunostaining and FISH. In: Fluorescence In Situ Hybridization (FISH), 301-325, 2016.
- Ye JC, Lawrenson L, Liu G, Stevens JB, Ye KJ, Bremer SW, and Heng HH. Simultaneous fluorescence immunostaining and FISH. In: Fluorescence in situ hybridization (FISH) Application, 193-216, 2009.
Books (edited and written)
- Heng, H.H., Ye, J.C.. Cancer Cytogenetics and Cytogenomics (Methods in Molecular Biology Series), 2023.
Grant & Contract Support
| Title: | Decipher Immune Signatures and Therapeutic Response in Multiple Myeloma Patients |
| Funding Source: | The Joint Institute for Translational and Clinical Research |
| Role: | Principal Investigator |
| Title: | Phase 2 Study with Minimal Residual Disease (MRD) driven adaptive strategy in treatment for newly diagnosed multiple myeloma with upfront daratumumab-based therapy |
| Funding Source: | Janssen Scientific Affairs |
| Role: | Principal Investigator |
| Title: | A Phase Ib/II Open-Label Study of APG2575 in Combination with Novel Therapeutic Regimens in Subjects with Relapsed or Refractory Multiple Myeloma and Immunoglobulin Light Chain Amyloidosis Ascentage- 22-PAF02911 |
| Funding Source: | Multiple Myeloma Research Foundation |
| Role: | Principal Investigator |
| Title: | Phase 1/2 FIH Study Of Regn5459 (Anti-Bcma X Anti-Cd3 Bispecific Antibody) In Patients With Relapsed Or Refractory Multiple Myeloma |
| Funding Source: | Regeneron Pharmaceuticals |
| Role: | Co-Investigator |
| Title: | A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12) |
| Funding Source: | GlaxoSmithKline LLC |
| Role: | Principal Investigator |
| Title: | Phase III Study of Daratumumab/rhuPH20 (NSC-810307) + Lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy inpatients with multiple myeloma using minimal residual disease to direct therapy duration (drammatic M-Cube Grant: Functional and clinically relevant T/NK cell subset screening from deep immune profiling in multiple myeloma using CYTOF |
| Funding Source: | MCube |
| Role: | Principal Investigator |
| Title: | A Phase 1, Open-Label, Multi-Center, Dose Escalation And Dose Expansion Study Of Nktr-255 As A Single Agent In Relapsed Or Refractory Hematological Malignancies And In Combination With Daratumumab As A Salvage Regimen For Multiple Myeloma |
| Funding Source: | Nektar Therapeutics |
| Role: | Principal Investigator |
| Title: | Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma |
| Funding Source: | Janssen Research and Development |
| Role: | Principal Investigator |
| Title: | A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma |
| Funding Source: | GSK |
| Role: | Principal Investigator |
| Title: | Clinical-Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies |
| Funding Source: | Multiple Myeloma Research Foundation |
| Role: | Principal Investigator |
| Title: | Participation Agreement for PINR (MMRC-060): Phase II trial of IXAZOMIB and Dexamethasone versus IXAZOMIB, Dexamethasone and Lenalidomide, Randomized with NFKB2 rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR) |
| Funding Source: | Millennium Pharmaceuticals |
| Role: | Principal Investigator |
| Title: | Clinical Trial Agreement for Protocol 13-601: A phase 1/2a open-label, multi-dose, multi-center escalation and exploratory study of cerdulatinib (prt062070) in patients with relapsed/refractory chronic lymphocytic leukemia (cll)/ small lymphocytic lymphoma (sll) or b-cell or t-cell non-hodgkin lymphoma (nhl) |
| Funding Source: | Portola Pharmaceuticals |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified September 16, 2024